Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
News|Articles|February 16, 2022
Thermo Fisher Scientific Unveils New CGT Services
Author(s)Pharmaceutical Technology Editors
Thermo Fisher Scientific's solution for cell and gene therapies involves a combination of cold chain logistics, serialization compliance, and distribution
Advertisement
Cell and gene therapy (CGT) companies can now use new integrated commercial packaging and distribution services from Thermo Fisher Scientific, the company announced on Feb. 15, 2022. The services are designed to facilitate the transition of cell and gene therapies from clinic to commercial launch for patients across the United States and Europe.
Patheon, a Thermo Fisher Scientific company, is offering commercial packaging services for CGT as an end-to-end solution that combines the good manufacturing practice (GMP) storage, serialization, ultracold and cryogenic packaging, and global distribution that developers need to support their logistics plans.
Some priorities surrounding the new services include:
- Regulatory-compliant serialization: support for the Drug Supply Chain and Security Act (DSCSA) and Falsified Medicines Directive (FMD) designed to ensure that product identity required for allogeneic products is maintained throughout the entire supply chain.
- Global infrastructure: packaging and distribution services available at cryocenters in Frederick, MD, and Weil-am-Rhein, Germany, support commercial launches in the US and European Union.
- Clinical to commercial scalability: experienced project teams with expertise in clinical trials designed to enable commercial success.
“There is a large number of cell and gene therapies reaching commercialization in the next few years that will make a significant impact in patients’ lives,” said Chris Armstrong, president, clinical trial services, Thermo Fisher Scientific, in a company press release. “Our integrated services are specifically designed to meet specialized needs for cell and gene therapies to ensure supply chain integrity from manufacturing through packaging, labeling, and distribution. This will help accelerate the introduction of these important life-saving medicines.”
Source: Thermo Fisher Scientific
Advertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement